Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition

Juan Carlos Varela, Robert A. Brodsky

Research output: Contribution to journalReview articlepeer-review

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease of hematopoietic stem cells due to a mutation in the PIG-A gene leading to a deficiency of GPI-anchored proteins. Lack of two specific GPI-anchored proteins, CD55 and CD59, leads to uncontrolled complement activation that result in both intravascular and extravascular hemolysis. Free hemoglobin leads to nitric oxide depletion that mediates the pathophysiology of some of the common clinical signs of PNH. Clinical symptoms of PNH include evidence of hemolytic anemia, bone marrow failure, smooth muscle dystonias and thromboses. Treatment options for patients with PNH include bone marrow transplantation, a therapy associated with high morbidity and mortality, or treatment with the complement inhibitor eculizumab. Eculizumab is a first-in-class anti-complement drug that in PNH has been shown to block complement-mediated hemolysis, reduce transfusion dependency, reduce thromboembolic complications and improve the quality of life (QoL) of patients.

Original languageEnglish (US)
Pages (from-to)1113-1124
Number of pages12
JournalExpert review of clinical immunology
Volume9
Issue number11
DOIs
StatePublished - Nov 14 2013

Keywords

  • complement inhibition
  • eculizumab
  • paroxysmal nocturnal hemoglobinuria

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition'. Together they form a unique fingerprint.

Cite this